Thus, our findings implicate that we should transiently or periodically activate autophagy to increase insulin sensitivity in insulin-responsive tissues without affecting the insulin load in islets (or increase both insulin sensitivity and β cell function), in future therapeutic development against T2D via modulating the autophagy activity. This evidence concerns the gene INS and type 2 diabetes mellitus.